Investor Relations
December 29, 2006  
NovaDel Closes on $14 Million Financing

December 20, 2006  
NovaDel Issued Second Canadian Patent for Oral Spray Delivery of Major Classes of Pharmaceuticals

December 15, 2006  
NovaDel Announces $14 Million Financing

December 15, 2006  
NovaDel Reports First Quarter Results

December 5, 2006  
NovaDel Appoints David Bergstrom as Chief Operating Officer

November 3, 2006  
NovaDel Pharma Receives FDA Approval of NitroMist(TM)

October 31, 2006  
NovaDel Announces Positive Results from Pilot Study of Zolpidem Oral Spray vs. Ambien(R) Tablets

October 30, 2006  
NovaDel Reports Fourth Quarter and Full Year Fiscal 2006 Financial Results

October 25, 2006  
NovaDel Pharma to Present at SIG Emerging Trends 2006 Conference November 1

September 28, 2006  
NovaDel Announces Positive Results from Pharmacokinetic Study of Improved Sumatriptan Oral Spray Formulation

Page 1 Of 3  
Next





Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.

Please note that the information in each of the press releases referenced here is only current as of the date of the release. NovaDel Pharma Inc. undertakes no obligation to update the information in the press releases to reflect new information, the occurrence of future events or circumstances, or otherwise.